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Abstract: Age-related macular degeneration (AMD) is responsible for more than half the 
blind registration in the United Kingdom. Retinal manifestations of AMD can be categorized 
as either atrophic or neovascular. The hallmark of AMD is the development of choroidal neo-
vascularization (CNV). Until recently, there have been few, limited treatment modalities (eg, 
photodynamic therapy [PDT]) for this condition and the mainstay of treatment has comprised 
social and lifestyle support. However, increased understanding of the molecular processes at 
work in neovascular AMD and CNV in recent years has led to the introduction of new anti-
angiogenic agents that target vascular endothelial growth factor (VEGF). These agents either 
inhibit a selected VEGF isoform (eg, VEGF165 inhibition by pegaptanib sodium) or inhibit all 
forms of the VEGF isoform (eg, non-selective VEGF blockade by ranibizumab). The trial data 
suggest that non-selective inhibition of VEGF offers better treatment outcomes in neovascular 
AMD. As a result, agents that inhibit all VEGF isoforms are now widely used as ﬁ  rst-line 
therapy for this condition. However, it is known that VEGF plays an important role in main-
taining the intergrity of the cardiovascular system and, particularly as the age of patients with 
AMD places them at an elevated risk of thromboembolic events, long-term post-marketing 
surveillance data are essential to determining whether non-selective VEGF blockade confers any 
increased risk. Theoretically, selective VEGF inhibition may reduce any risk associated with 
pan-VEGF blockade, yet on the basis of initial trials, their use remains more limited at this time. 
However, clinical practice suggests that initial trials may have under-estimated the efﬁ  cacy of 
selective-VEGF inhibition. Observational studies also indicate that better treatment outcomes 
may be possible by combining VEGF inhibitors sequentially with each other, or with existing 
therapies (eg, photodynamic therapy [PDT]). The optimum role and indications of anti-VEGF 
agents will come through careful consideration of the available efﬁ  cacy and safety data, from 
the outcomes of long-term follow-up studies, and through assessment of the relative merits of 
the two approaches to VEGF inhibition in clinical practice. At this time, further head-to-head 
trials, and economic evaluations, comparing the treatment alternatives are needed.
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The disease burden
Age-related macular degeneration (AMD) is the leading cause of blindness in the 
western world’s elderly population (Klein et al 1992). The early form of the disease 
is characterized by the presence of drusen in the central macula and/or retinal pig-
ment epithelial (RPE) changes; it is often referred to as age-related maculopathy 
(ARM). More advanced AMD – which can take either a neovascular/exudative/wet 
form characterized by choroidal neovascularization (CNV), or a dry form – can lead 
to severe visual loss.
Dry AMD is associated with a very gradual loss of vision and is responsible for 
20% of the legal blindness owing to AMD. Neovascular AMD is responsible for the 
other 80% and has a more variable course. Disease progression tends to be quicker Clinical Ophthalmology 2008:2(2) 340
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with neovascular AMD and visual acuity (VA) can change 
from normal vision to legal blindness within a matter of 
weeks (Ferris et al 1984).
Worldwide, there are approximately 500,000 new cases of 
neovascular AMD diagnosed annually (Bressler et al 2003). 
In the United Kingdom (UK), there is an estimated 245,000 
people living with neovascular AMD, and it represents more 
than 50% of the country’s blind registration (Evans 1995; 
Owen et al 2003). This huge public health impact promises 
to exact an even greater toll with the imminent demographic 
right-shift seen in increasingly aging populations.
Disease characteristics
The hallmark of neovascular AMD is the development 
of CNV. Patients may present with several pathological 
features, such as sub-retinal ﬂ  uid (SRF), hemorrhages and 
exudates, pigment epithelial detachments (PED), and retinal 
scarring. The CNV can develop directly under the center of 
the fovea (subfoveal CNV), in the remainder of the fovea 
(juxtafoveal CNV), or in the area of the macula excluding 
the fovea (extrafoveal CNV). Angiographically, a neovas-
cular lesion is classiﬁ  ed depending on the amount of classic 
CNV present: lesions with 50% classic CNV are termed 
predominantly classic lesion, while lesions with 50% clas-
sic CNV are deﬁ  ned as minimally classic lesions. Lesions 
with no classic CNV are termed occult lesions. Those lesions 
with classic neovascular membranes are associated with 
faster progression to legal blindness than occult neovascular 
membranes (Bressler et al 2002).
Disease management
The mainstay of existing treatment for dry AMD and for the 
advanced neovascular form of the condition comprises social 
support, visual rehabilitation, and provision of low vision 
aids. The traditional treatment modalities for wet AMD are 
few and, at best, halt disease progression (Macular Photo-
coagulation Study Group 1993; Treatment of Age-Related 
Macular Degeneration with Photodynamic Therapy [TAP] 
Study Group 1999).
Laser photocoagulation
Laser photocoagulation was the ﬁ  rst evidence-based treat-
ment option found to be beneﬁ  cial in certain subtypes of 
neovascular membranes. It is possible to treat well-deﬁ  ned, 
classic, extrafoveal lesions with an argon, krypton, or diode 
laser. The aim of laser treatment is to halt the rapid visual 
loss caused by progression of CNV within the retinal mem-
branes. However, treatment is limited and is associated with 
high recurrence rates (up to 50%), limited lesion eligibility 
for treatment (only 10%–15%), and an immediate drop in 
vision when used for the treatment of subfoveal CNV (Macular 
Photocoagulation Study Group 1993).
Photodynamic therapy
In 2000, the Food and Drug Administration (FDA) and 
European Agency for the Evaluation of Medicinal Products 
(EMEA) approved verteporﬁ  n (Visudyne®; QLT Therapeu-
tics, Inc, Vancouver, British Columbia, Canada, and Novartis 
Ophthalmics, Bulach, Switzerland) for use in patients with 
predominantly classic, subfoveal CNV secondary to AMD. 
In the UK, the National Institute for Health and Clinical 
Excellence (NICE) has also endorsed the use of photody-
namic therapy (PDT) with verteporﬁ  n for the treatment of 
subfoveal, predominantly classic lesions (with no occult 
subfoveal CNV) (NICE 2003). PDT has two components; 
injection of a photosensitive agent and subsequent applica-
tion of a low-energy laser to the affected areas of the retina. 
Akin to laser photocoagulation, the approach aims to prevent 
further loss of vision by halting progression in the neovas-
cular membranes. Both treatment modalities are destructive 
procedures (Bressler and Bressler 2000), but a new treatment 
avenue has been opened through recent research that has led 
to the development of targeted therapies for AMD.
Targeted therapies
Understanding of the molecular processes at work in AMD 
and CNV has increased signiﬁ  cantly in the last decade. Sev-
eral lines of evidence indicate a multi-factorial etiology, one 
that involves a combination of genetic factors, inﬂ  ammation, 
accumulation of lipid and metabolic by-products, oxidative 
stress and alterations in the Bruch’s membrane (Ambati 
et al 2003). Responding to these stresses, the RPE and retina 
produce various growth factors such as vascular endothelial 
growth factor (VEGF), ﬁ  broblast growth factor-2, and pig-
ment epithelium-derived growth factor (Dorrell et al 2007). 
Although VEGF is integral to the physiological processes 
that require angiogenesis (such as embryogenesis, somatic 
growth and tissue repair) (Stephan and Brock 1996), it is also 
implicated as central to the pathological processes involving 
neovascularization, such as the development of CNV (Lopez 
et al 1996; Bhisitkul 2006).
Rationale for targeting VEGF 
in neovascular AMD
VEGF acts as an endothelial-cell chemo-attractant and anti-
apoptotic agent, leading to endothelial-cell proliferation, Clinical Ophthalmology 2008:2(2) 341
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survival, and migration, as well as to increased vascular 
hyperpermeability. It induces the expression of urokinase- and 
tissue-type plasminogen activators, as well as metalloprotein-
ase interstitial collagenase (Ferrara 2004). This co-induction 
promotes degradation of the local extracellular matrix and 
facilitates endothelial cell migration (Ng and Adamis 2005).
VEGF is a member of the platelet-derived growth factor 
family, and its production is often stimulated by tissue 
hypoxia or other growth factors (Pertovaara 1994). The 
VEGF gene gives rise to various polypeptides, including 
the 121-, 165-, 189-, and 208-amino acid isoforms 
(Ng and Adamis 2005). Each VEGF isoform has unique 
characteristics, and VEGF165 is the form most abundant in 
the human eye, although it is ubiquitously distributed (Houck 
et al 1991). VEGF binds to two receptors, VEGFR-1 and 
VEGFR-2, and this binding activates signal transduction 
cascades (Usui et al 2004).
Several studies have investigated the role of VEGF in 
ocular neovascularization (Aiello et al 1994; Pierce et al 
1996), and VEGF has been implicated in the development 
of retinal and iris neovascularization in ischemic diseases 
such as diabetic retinopathy (Adamis et al 2006), retinal 
vein occlusion (Pe’er et al 1998), retinopathy of prematurity 
(Chen and Smith 2007), and neovascular glaucoma (Tripathi 
et al 1998). In addition, evidence has also emerged to sug-
gest a putative role for VEGF in CNV. VEGF levels have 
been found to be increased in the RPE and choroidal blood 
vessels of maculae exhibiting AMD (Frank et al 1996). The 
growth factor induces proliferation of choroid endothelial 
cells in non-human primates (Tolentino et al 1996), and 
adenoviral transfection of the VEGF gene into the RPE of 
rats has been shown to lead to the development of CNV 
(Bafﬁ   et al 2000).
Inhibition of VEGF can also impede the formation of 
CNV in experimental models: intravitreous (ITV) injection 
of an oligonucleotide targeted to the VEGF sequence has 
been shown to inhibit laser-induced CNV in rats (Eyetech 
Study Group 2002). In addition, repeated ITV injections of 
rhuFabV2, an active fragment of a recombinant humanized 
monoclonal VEGF antibody, inhibits the development of 
laser-induced CNV in a primate model (Eyetech Study Group 
2002). These observations, which provide a sound rationale 
for targeting VEGF in an attempt to impede the progress of 
CNV, combined with recent advances in directed molecular 
interventions (eg, monoclonal antibodies, aptamers, ribo-
zymes, gene transfer therapy) have paved the path to the 
development of several anti-VEGF agents in the treatment 
of neovascular AMD (Dorrell et al 2007).
Selective VEGF inhibition
Pegaptanib sodium (Macugen®, [OSI] Eyetech Pharmaceuticals, 
Pﬁ  zer) is the ﬁ  rst targeted anti-VEGF therapy available for 
the treatment of CNV (Krzystolik et al 2002). The agent 
belongs to a new class of therapeutic drugs called aptamers. 
Aptamers are synthetic oligonucleotides that adopt a speciﬁ  c 
three-dimensional conformation that allows them to bind, with 
high speciﬁ  city and afﬁ  nity, to a wide range of therapeutic 
agents. These compounds are chemically synthesized from 
component nucleotide bases with reverse transcription and 
polymerase chain reaction technologies (Gragoudas et al 
2004). Pegaptanib sodium is a 28-base ribonucleic acid (RNA) 
oligonucleotide with two branched 20 kDa polyethylene gly-
col (PEG) moieties attached in order to increase the half-life 
of the drug in the vitreous cavity. The RNA sugar background 
is modiﬁ  ed to prevent its degradation by endogenous endo- 
and exo-nucleases. Pegaptanib sodium speciﬁ  cally targets the 
VEGF165 isoform (Waheed et al 2004).
Phase I and II studies have evaluated the safety and efﬁ  -
cacy of pegaptanib sodium as a therapy for subfoveal CNV 
secondary to AMD and have demonstrated that, given every 
6 weeks, pegaptanib sodium provides anatomic and visual 
beneﬁ  ts (Ruckman et al 1998).
The VISION study
The VEGF Inhibition Study in Ocular Neovascularisation 
(VISION) consists of two concurrent, prospective, dose-
ranging, multi-center (involving 117 centers and 1208 patients), 
randomized controlled trials (RCTs) that were conducted to 
assess the safety and efﬁ  cacy of pegaptanib sodium in patients 
with CNV secondary to AMD (Gonzales and VISION Clinical 
Trial Group 2005). The VISION study population was broad, 
including patients aged 50 years with any angiographic 
subtype of subfoveal CNV in the study eye. Any lesion 12 
disc areas, with scarring 25% and hemorrhage 50% of the 
total lesion size, was eligible for inclusion. The best corrected 
VA of the study eye ranged between 20/40 and 20/320. Patients 
were randomly assigned either to sham injection or ITV injection 
of 0.3 mg, 1 mg or 3 mg pegaptanib sodium. Injections were 
administered every 6 weeks for a total of 48 weeks (equating 
to nine separate injections). Patients receiving sham or study 
medications were treated identically except for the absence of 
scleral penetration in the sham patient group. All treatment arms 
allowed treatment with PDT with verteporﬁ  n (Visudyne) for 
predominantly classic CNV to ensure that the sham group was 
equivalent to usual care treatment for neovascular AMD.
The primary study outcome measure was the propor-
tion of patients who lost 15 letters of VA (deﬁ  ned as Clinical Ophthalmology 2008:2(2) 342
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3 lines on the study eye chart) at the end of week 54. 
Additional efﬁ  cacy end-points included: proportion of 
patients maintaining or gaining 0, 5, 10, or 15 letters, 
or losing 30 letters; mean changes in VA from baseline 
to week 54, at 6-weekly intervals, and the proportion of 
patients with VA of 20/200 or worse in the study eye at 
week 54.
Of the 1208 patients involved in the study, 296 patients 
were randomized to receive sham injections; 294 to receive 
0.3 mg pegatanib sodium ITV; 300 to receive 1 mg pegaptanib 
sodium ITV; and 296 to receive 3 mg pegaptanib sodium 
ITV. Overall, the 0.3 mg dose was found to be most effective, 
regardless of angiographic sub-type or lesion size. A com-
parison of the outcomes recorded in the 0.3 mg pegaptanib 
sodium and sham study arms is summarized in Table 1.
The average number of PDT treatments required per 
patient post baseline was lower in the 0.3 mg pegaptanib 
sodium study arm (1.44) than in the sham study arm (2.33). 
The 2-year data show that patients who continued with pegap-
tanib sodium treatment for 2 years experienced less vision loss 
than those patients who discontinued treatment (see Table 2). 
Analysis of the data also indicated that there was no evidence 
that any angiographic subtype of the lesion, level of VA at 
baseline, or lesion size precluded a treatment beneﬁ  t.
Safety
Adverse events, such as vitreous ﬂ  oaters and inﬂ  amma-
tion, were more frequently noted among patients receiving 
pegaptanib sodium than those administered sham injections. 
Serious adverse events with pegaptanib sodium included 
endophthalmitis (16/11636 injections), retinal detachment 
(13/11636 injections), and iatrogenic traumatic cataract 
(6/11636 injections). No increased risk of systemic adverse 
events was noted, but patients with high risk of cardiovas-
cular and cerebrovascular events were excluded from the 
clinical trials.
Role of pegaptanib sodium
Pegaptanib sodium was the ﬁ  rst anti-VEGF licensed for 
the treatment of CNV due to neovascular AMD. As under-
standing of the role of VEGF in the pathogenesis of CNV 
increases, many more trials are now turning their focus to 
the VEGF molecule. The beneﬁ  t of pegaptanib sodium is 
that its efﬁ  cacy is not dependent on lesion subtypes, lesion 
size, or baseline VA, allowing more patients to be eligible 
for treatment.
It is an aptamer and binds to VEGF with high speciﬁ  c-
ity and afﬁ  nity. It targets only VEGF165 and, as a result, is 
assumed not to interfere with other physiological actions of 
other isoforms of the molecule. Trial data demonstrate that 
the treatment effect occurs early and is sustained for 2 years, 
although the efﬁ  cacy in the second year appears to decrease. 
The drug was found to be relatively safe over 2 years, and 
most adverse events reported in the study eyes were attributed 
to the injection procedure. The cumulative risk of endophthal-
mitis was found to be low in these trials.
Non-selective VEGF inhibition
Ranibizumab
Other anti-VEGF agents are now being used in the treatment 
of neovascular AMD. Ranibizumab (Lucentis®, Genentech, Inc) 
is an antibody binding site fragment with a molecular weight 
of 48 kDa that is derived from a murine anti-VEGF antibody 
and is produced in an Escherichia coli expression system that 
is not glycosylated. It is a non-selective inhibitor of VEGF-A 
(Eyetech Study Group 2003). Data from two pivotal Phase III 
clinical trials on ranibizumab (Minimally classic/occult trial 
of the Anti-VEGF antibody Ranibizumab In the treatment of 
Table 1 Comparison of outcomes in the 0.3 mg intravitreous 
pegaptanib sodium and sham injection patient groups at week 54
 Pegaptanib  Sham  p-value
 (0.3  mg)  n  = 296
 n  = 294 
Proportion that lost   70%  55%  0.001
fewer than 15 letters
Mean visual loss (letters)  7.93  15.05  0.050
Proportion that maintained  33%  23%  0.003
or gained vision
Proportion that gained   22%  12%  0.050
5 letters
Proportion that gained   11%  6%  0.050
10 letters
Proportion that gained   6%  2%  0.050
15 letters
Proportion with severe   10%  22%  0.001
visual loss
Proportion with vision   38%  56%  0.001
20/200
Table 2 Impact of treatment discontinuation on visual outcome 
at week 102
  Continued pegaptanib  Discontinued
 sodium  (n  = 133)  pegaptanib
   sodium  (n  = 132)
Mean visual loss  0.6 letters  5.3 letters
Loss of 15 letters  15.8%  26.5%
Loss of 30 letters  2.3%  4.7%Clinical Ophthalmology 2008:2(2) 343
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Neovascular AMD [MARINA] and Anti-VEGF Antibody 
for the Treatment of Predominantly Classic Choroidal 
Neovascularization in AMD [ANCHOR]) demonstrate 
that nearly all patients (approximately 95%) treated with 
ranibizumab (0.5 mg) maintained vision, and 40% reported 
vision improvement, at 1 year (Gaudreault et al 2005; Brown 
et al 2006; Rosenfeld et al 2006; Campochiaro 2007).
Patients treated with ranibizumab for minimally classic 
and occult lesions in the MARINA study experienced an 
improvement from baseline of 6.6 letters at 2 years compared 
with a loss of 14.9 letters in the sham study arm (Rosenfeld 
et al 2006). In the ANCHOR study, patients treated with 
ranibizumab for predominantly classic lesions experienced 
(on average) an 11.3 letter gain from baseline at 1 year 
compared with a loss of 9.5 letters in the PDT control group. 
Moreover, 40% of patients treated with ranibizumab achieved 
vision of 20/40 or better.
Bevacizumab
Bevacizumab (Avastin®, Genentech, Inc) is a full-length 
humanized monoclonal antibody to VEGF. It is produced 
in a Chinese hamster ovary mammalian cell system that is 
glycosylated, and it is designed and approved for intravenous 
administration for the treatment of metastatic colonic cancer. 
Similar to ranibizumab, it blocks all isoforms of VEGF-A, 
but importantly, the active binding sites of bevacizumab 
differ from those of ranibizumab. It has a molecular weight 
of 149 kDa and has 100 times less binding afﬁ  nity than 
ranibizumab (Steinbrook 2006).
Despite the differences between these two pan-VEGF 
inhibitors, it is well-hypothesized that bevacizumab is as 
effective as ranibizumab. Recently, several clinical series 
using ITV bevacizumab for the treatment of CNV secondary 
to AMD have shown promising results, reporting consider-
able improvement in VA, a reduction in retinal thickening 
(as detected from optical coherent tomography [OCT]) and 
no marked short-term toxicity (Cleary et al 2007; Emerson 
et al 2007; Wu et al 2008). However, due to its substantially 
higher molecular weight, local and systemic clearance of 
bevacizumab may be delayed, which could allow extended 
durability of effect of treatment and may result in higher 
systemic toxicity than ranibizumab.
VEGF inhibition and 
thromboembolic risk
The difference between these two approaches to VEGF 
inhibition is that pegaptanib sodium is a selective inhibitor of 
VEGF-A 165 isoform, while ranibizumab and bevacizumab 
are pan-VEGF-A blockers. The doses of the three agents used 
are small, but the plasma half-lives of both pegaptanib sodium 
(Macugen AMD Study group 2007) and bevacizumab are 
long compared with that of ranibizumab (Bakri et al 2007). 
Despite this, the peak plasma concentrations of pegaptanib 
sodium and ranibizumab are below 11–27 ng/mL, the level 
necessary to inhibit the biologic activity of VEGF-A by half. 
However, the peak plasma concentration recorded for beva-
cizumab is substantially higher (Wong et al 2007).
The physiological level of serum VEGF is 100 pg/mL 
(Larsson et al 2002). Physiologically, VEGF is required 
for both the integrity of the cardiovascular system and, 
pathologically, for re-perfusion of ischemic tissues (eg, the 
myocardium following myocardial infarction [MI] and the 
brain following stroke) (Zlokovic 2006; Infanger et al 2007). 
The supposition is, therefore, that chronic pan-VEGF block-
ade may increase cardiovascular risk. A recent report also 
suggested that the overall rates of arterial thromboembolic 
events recorded in MARINA were lower than those noted 
in population-based studies, suggesting selection bias due to 
under-recruitment of patients with existing cardiovascular 
disease (Liew et al 2007).
Wong et al suggest that AMD may be a marker of high 
cardiovascular risk (Wong et al 2007). Furthermore, analysis 
of safety outcomes in trials of ranibizumab reports a signiﬁ  cant 
increase in non-ocular hemorrhage in the treatment arms (Liew 
et al 2007). Similarly, a recent interim analysis of the safety 
data on ranibizumab for the treatment of neovascular AMD 
(the on-going Safety Assessment of Intravitreal Lucentis fOR 
AMD [SAILOR] study) reported a higher rate of stroke in the 
patients with a prior history of stroke randomized to 0.5 mg 
ranibizumab (9.6%) compared with the rate recorded in those 
randomized to receive 0.3 mg ranbizumab (2.7%) (Genentech 
2007). However, this trend is inconclusive and the analysis did 
not ﬁ  nd any difference in rate of MI or cardiovascular deaths 
between the two treatment groups. These data highlight the 
need for, and importance of, carrying out thorough assess-
ment of long-term, post-marketing surveillance data regarding 
these agents. Clinicians providing high-volume ranibizumab 
services have a responsibility to audit and report adverse 
events (as and when they occur) with a view to establishing 
an evidence base that will help the community to understand 
the true estimate of any treatment-related adverse events.
Selective versus non-selective 
VEGF inhibition
The superior trial results for ranibizumab have made it the 
drug of choice for neovascular AMD. At this time, the role Clinical Ophthalmology 2008:2(2) 344
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of selective inhibition of the VEGF165 isomer remains more 
limited, unless the safety concerns associated with long-term 
pan-VEGF blockade are conﬁ  rmed. However, in clinical 
practice, it may be useful to consider pegatanib sodium as a 
second-line agent that could be used in patients with recent 
thromboembolic phenomena. In this vein, it may be advisable 
to use pegatanib sodium as a maintenance therapy in patients 
requiring prolonged treatment (Friberg et al 2007). As the 
maximum gain in vision recorded with ranibizumab treatment 
was obtained with the ﬁ  rst four treatments in the MARINA 
and ANCHOR studies (Brown et al 2006; Rosenfeld et al 
2006), it may also be prudent to consider the use of pegaptanib 
sodium as a secondary agent in order to maintain the effect of 
therapy. A recent study involving 20 patients, with all CNV 
subtypes, who were treated with bevacizumab induction 
followed by pegaptanib sodium maintenance therapy, 
demonstrated an improvement in clinical outcomes and 
acceptable safety proﬁ  les using the combined selective- and 
non-selective VEGF regimen (Hughes and Sang 2006). This 
hypothesis is being examined in the on-going evaLuation 
of Efﬁ  cacy and safety in maintaining Visual acuity with 
sEquential treatment of neovascuLar AMD (LEVEL) study 
(Friberg et al 2007).
Clinical implications
Due to the nature of the existing evidence, there remains 
uncertainty over the relative beneﬁ  ts of pegaptanib sodium 
compared with ranibizumab and bevacizumab. Head-to-head 
RCTs and economic evaluations comparing the treatment 
alternatives are needed.
Based on the pivotal trials of pegaptanib sodium and 
ranibizumab, pegaptanib sodium has a more limited role as 
ﬁ  rst-line therapy for neovascular AMD. However, explor-
atory analysis of the VISION study demonstrates better 
treatment response with pegaptanib sodium in early lesions 
(Gonzales and VISION Trial Group 2005). Similarly, real-
life, clinical experience with pegaptanib sodium shows 
greater effectiveness than the results of the VISION study 
may suggest (Quiram et al 2007). It may also be useful to
further investigate the effect of pegaptanib sodium in the 
patient group who responded best to treatment in the ranibi-
zumab MARINA trial – those patients with small occult 
lesions with recent disease progression (Quiram et al 2007).
The different mechanisms of action of PDT with verte-
porﬁ  n and anti-angiogenic agents such as VEGF inhibitors 
offers the potential for synergistic effects with combination 
therapy. Verteporﬁ  n targets the present vascular compo-
nent, whereas anti-angiogenic agents target key mediators 
of the angiogenic cascade. In addition, anti-angiogenic 
agents might counteract up-regulation of angiogenic factors 
(including VEGF) that occur after PDT with verteporﬁ  n 
(Schmidt-Erfurth et al 2003). Results from preclinical 
and clinical studies of combining pegaptanib sodium or 
ranibizumab with PDT with verteporﬁ  n warrant continued 
investigation (Brown et al 2006; Dhalla et al 2006; Liggett 
et al 2006; Heier et al 2006; Lazic et al 2007). The 1-year 
results of the FOCUS study demonstrate that combining 
ranibizumab with PDT with verteporﬁ  n is more effective 
than treatment with PDT with verteporﬁ  n alone (Heier et al 
2006). Such combinations may reduce the need for repeated 
treatments.
Cost-effectiveness
Cost-effectiveness is another criterion against which treat-
ment choice in neovascular AMD is assessed. However, 
based on the trial data currently available, it is difﬁ  cult to 
estimate the true pharmacoeconomic beneﬁ  t one agent offers 
over another. For example, the cost-effectiveness data of 
pegaptanib sodium are extrapolated from data obtained in 
the VISION study, but real-life clinical experience indicates 
that treatment with pegaptanib sodium may offer better clini-
cal efﬁ  cacy than the outcomes of the VISION study might 
suggest. Moreover, the number of injections each patient 
requires is dependent on clinical judgment and patient choice, 
both subjective factors that may show wide variation due to 
the absence of strict discontinuation criteria. Many medical 
retina specialists follow the re-treatment criteria used in the 
Prospective OCT imaging of patients with Neovascular AMD 
Treated with intraOcular ranibizumab (PrONTO) study (Lal-
wani et al 2007). However, OCT may fail to identify lesions 
with central atrophy and ﬁ  brosis, which can also be useful 
indicators of discontinuation (personal experience).
A recent study expressed cost-effectiveness as the incre-
mental cost (IC) per vision-year saved and IC per quality-
adjusted life year (QALY). When treatment was targeted to 
patients with a VA of 6/12 to 6/95 and discontinued after 
2 years, or earlier if the VA fell below 6/95 or by 6 lines, 
the IC/QALY was estimated at £8,023 (upper 95% CI 
£20,641) (Wolowacz et al 2007). The study also concluded 
that pegaptanib sodium was more cost-effective in patients 
75 years of age and with better baseline VA (range 6/12 to 
6/24) (Wolowacz et al 2007). Value-based medicine analysis 
of clinical trials that evaluated the interventions of laser pho-
tocoagulation, ITV pegaptanib sodium, and PDT with verte-
porﬁ  n for the treatment of classic, subfoveal CNV show that 
laser photocoagulation confers an improvement in quality of Clinical Ophthalmology 2008:2(2) 345
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life of 4.4% compared with 5.9% with pegaptanib sodium, 
and an improvement of 8.1% with PDT (Brown et al 2007a). 
Preliminary data suggest the value gain for the treatment of 
occult/minimally classic CNV with ranibizumab is greater 
than 15% (Brown et al 2007b). These interventions provide 
much better value than many routinely used medicines such 
as statins for the treatment of hyperlipidemia, which offer an 
average quality of life gain of 3.9% (Brown et al 2007b). The 
economic burden of AMD on the National Health Service as 
a single entity has not been rigorously assessed and quanti-
ﬁ  ed, and analysis thus far has been based on reported blind 
registration and prevalence studies. Moreover, a signiﬁ  cant 
number of patients with neovascular AMD may remain 
mis- or undiagnosed.
Conclusions
There is now a selection of agents for the treatment of neo-
vascular AMD on offer, and treatment choice should take into 
consideration clinical rationale (including the safety proﬁ  le 
of the available therapies) and cost-effectiveness. The role 
of pegaptanib sodium may be that of a maintenance agent, 
after induction with a pan-VEGF inhibitor, especially in 
patients who have been subject to recent MI and stroke. Only 
clinical trials focused in these areas, combined with analysis 
of post-marketing surveillance of the new anti-angiogenic 
agents, will help further deﬁ  ne the optimal indications for 
the selective VEGF165 inhibitor.
In the light of the changing treatment paradigm brought 
about by the introduction of anti-angiogenic agents in neo-
vascular AMD, many ophthalmology departments now offer 
fast-track AMD diagnostic services. These services not only 
facilitate efﬁ  cient administration of the new therapies, but 
also aim to provide better education of the public, optom-
etrists and ophthalmologists. Better education, fuelled by 
signiﬁ  cant media interest in the area, may combine to help 
improve diagnosis and minimize the impact of the condition 
on the healthcare service.
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